TABLE 4.

Investigator assessment of clinical response to omadacycline (safety population)

Parameterb	No. (%) of patients in groupa:
	1 (i.v. 200 mg → p.o. 300 mg [n = 11])	2 (p.o. 300 mg [n = 10])	3 (p.o. 450 mg [n = 10])
End of treatment
Clinical success	10 (90.9)	10 (100)	9 (90.0)
Clinical failure	0	0	1 (10.0)
Indeterminate	1 (9.1)	0	0
Posttreatment evaluation
Clinical success	11 (100)	7 (70.0)	8 (80.0)
Clinical failure	0	2 (20.0)	2 (20.0)
Indeterminate	0	1 (10.0)	0

^aOmadacycline doses are given in parentheses after each group. i.v., intravenous; p.o., oral.

^bClinical success indicates resolution of signs and symptoms and no use of additional systemic antimicrobial therapy for the urinary tract infection. Clinical failure indicates no apparent response to therapy, persistence of signs and symptoms of infection at the end-of-treatment visit, or the use of additional systemic antimicrobial therapy for the current infection. Indeterminate indicates that the visit was not completed.